SEOUL, July 10 (Korea Bizwire) — Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, said Monday it has signed a US$390.9 million deal with Novartis Pharma AG to manufacture the Switzerland-based pharmaceutical firm’s products. It is the final contract for an investment letter of intent announced in June last year, in which [...]
EDMONTON, Alberta, April 21 (Korea Bizwire) — Translational Research In Oncology (TRIO) today announced completion of enrollment for Novartis phase III clinical trial of ribociclib with endocrine therapy in the adjuvant treatment of HR-positive, HER2-negative early breast cancer (EBC). The trial, referred to as NATALEE (New Adjuvant TriAl with LEE), has enrolled 5101 patients globally. [...]
Basel, Feb. 16 (Korea Bizwire) — Novartis today announced that the US Food and Drug Administration (FDA) has approved the following expanded indication for Entresto® (sacubitril/valsartan): to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure1. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) [...]
SEOUL, May 25 (Korea Bizwire) — South Korea’s health ministry said Wednesday it will suspend providing benefits for nine variations of two drug types manufactured by the local unit of Novartis after the Swiss pharmaceutical giant was found to have been engaged in illegal kickbacks. For six months starting in August, local customers will have [...]
SEOUL, April 10 (Korea Bizwire) – South Korea’s health authorities are considering a suspension of health insurance reimbursement for imatinib, a highly effective leukemia drug sold under the brand name of Gleevec (or Glivec), after its maker Novartis was found to have provided illegal kickbacks to doctors. The Swiss multinational pharmaceutical company was investigated by prosecutors [...]